During the last 10–15years, a large amount of evidence has accumulated about the incidence of atrial fibrillation (AF) in the population, its most important risk factors and subsequent outcomes. This tremendous progress has led to a better understanding of the disease and the development of novel therapeutic targets and strategies. I would like to give a brief overview of the most important advances in the next three paragraphs. I will also highlight some of the most important gaps of knowledge that persist.
Conen D. Eur Heart J. 2018;39:1323-4.